The Institute for Clinical and Economic Review, which analyzes drug prices, lowered its recommended price for Gilead’s remdesivir after accounting for results from the World Health Organization-funded Solidarity trial. The antiviral did not reduce the death rate among COVID-19 patients in the Solidarity trial. In the United States, remdesivir’s price is currently capped at $3,120 per treatment course, even though Gilead set a uniform price for all developed countries that is $780 lower than that. This price was set in...